Business Context and Reporting Period
This Form 8-K Current Report was filed by Syndax Pharmaceuticals, Inc. on December 20, 2023, covering events occurring on December 19, 2023. The filing reports the closing of a public offering of common stock and the full exercise of the underwriters' option to purchase additional shares.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification of a capital-raising event rather than a financial performance report.
Material Changes
- Capital Raise: The Company closed a public offering of common stock.
- Option Exercise: Underwriters exercised their option in full to purchase additional shares.
Guidance, Outlook, and Risks
The filing incorporates by reference a press release (Exhibit 99.1) regarding the offering but does not contain specific management commentary, forward-looking guidance, risk factors, or contingencies within the text of this 8-K form itself.
Investor Verification Checklist
- Verify the total number of shares sold and the offering price per share in the referenced press release (Exhibit 99.1).
- Confirm the total gross proceeds raised from the offering and the full exercise of the option.
- Review the updated capitalization table to assess dilution impact on existing shareholders.
- Check the use of proceeds disclosed in the press release to understand how the capital will be deployed.